Description

Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used in research for its glucose-lowering, renal-protective, and cardiovascular effects. It has gained prominence in experimental studies related to type 2 diabetes, heart failure, and metabolic syndrome.

This product contains 10mg of dapagliflozin per tablet, with 30 tablets per box, manufactured by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and approved under NMPA Registration No. H20233761.

?? For laboratory research use only. Not for human or veterinary use.

Product Specifications

Mechanism of Action & Research Applications

Dapagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion. This mechanism supports experimental work in:

• Glucose homeostasis

• Diabetic nephropathy

• Heart failure with preserved ejection fraction (HFpEF)

• Obesity and metabolic disorders

• Insulin resistance and inflammatory markers

Safety & Handling

• Dapagliflozin Use Restriction: For laboratory research only. Not for human or animal therapeutic use.

• Handling: Use personal protective equipment (PPE) including gloves, eye protection, and lab coats.

• Storage: Keep sealed and stored below 25°C. Avoid direct sunlight and high humidity.

• Disposal: Follow local institutional and environmental guidelines for pharmaceutical waste.

Research Use Disclaimer

Dapagliflozin exclusively for research use in controlled laboratory environments. It is not to be used in diagnostic, therapeutic, or veterinary settings. Mishandling or misuse may lead to safety or legal consequences. Users must follow institutional safety protocols and disposal procedures.